July 2015

Global Pharmaceutical Company Enters Into Joint Venture to Accelerate Drug Development

Our firm advised a global pharmaceutical company on the formation of a joint venture to develop antibody and protein-based therapeutics in the areas of immunology, hematology and oncology. The collaboration model is designed to advance promising therapies quickly through the development process, using each partner’s recognized expertise, with the pharmaceutical company partner holding an exclusive option to acquire each product following the completion of Phase I trials.

Related Legal Services

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.